Carbapenem-Resistant Enterobacteriaceae Bacteremia in Pediatric Patients in Latin America and the Caribbean: A Systematic Review and Meta-Analysis

被引:0
作者
Ruvinsky, Silvina [1 ,2 ]
Voto, Carla [1 ]
Roel, Macarena [1 ]
Portillo, Victoria [1 ]
Zuniga, Gabriela Naranjo [3 ]
Ulloa-Gutierrez, Rolando [3 ]
Comande, Daniel [2 ]
Ciapponi, Agustin [2 ,4 ]
Aboud, Gabriela [1 ]
Brizuela, Martin [5 ]
Bardach, Ariel [2 ,4 ]
机构
[1] Hosp Pediat Dr Juan P Garrahan, Coordinac Invest, RA-1245 Buenos Aires, Argentina
[2] Inst Efect Clin & Sanitaria, RA-1414 Buenos Aires, Argentina
[3] Hosp Nacl Ninos Dr Carlos Saenz Herrera, San Jose 10103, Costa Rica
[4] Consejo Nacl Invest Cient & Tecn, Ctr Invest Epidemiol & Salud Publ CIESP, IECS, RA-1414 Buenos Aires, Argentina
[5] Hosp Gen Agudos Velez Sarsfield, Unidad Pediat, RA-1550 Buenos Aires, Argentina
来源
ANTIBIOTICS-BASEL | 2024年 / 13卷 / 12期
关键词
carbapenem-resistant <italic>Enterobacteriaceae</italic>; bacteremia; children; Latin America and the Caribbean; meta-analysis; systematic review; BLOOD-STREAM INFECTIONS; RISK-FACTORS; KLEBSIELLA-PNEUMONIAE; OUTCOMES; CHILDREN;
D O I
10.3390/antibiotics13121117
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Data on the health impact of carbapenem-resistant Enterobacteriaceae bloodstream infections (CRE-BSIs) in pediatric populations from Latin America and the Caribbean (LAC) are limited. This systematic review aims to examine the demographic, clinical, and microbiological aspects and resource utilization of this infection in children from this region. Methods: This systematic review investigates the impact of CRE-BSIs in pediatric populations across LAC. Following the Cochrane methodology and PRISMA/MOOSE guidelines, we conducted an extensive search of different databases, including MEDLINE/PubMed, LILACS (SciELO), CENTRAL, CINAHL, Embase (Ovid), the Cochrane Library, and the World Health Organization (WHO) database, and relevant websites for published articles between January 2012 and September 2024. The review included studies on hospitalized patients under 19 years of age with CRE-BSIs. Results: Fourteen studies involving 189 patients were analyzed. Most cases were reported from Brazil, Argentina, Colombia, and Paraguay. The median age of the patients was 35 months. Key risk factors included immunocompromised status, invasive procedures, carbapenem use, and colonization. The infections were predominantly hospital-acquired, with Klebsiella pneumoniae and Serratia spp. being the most common pathogens. KPC and NDM were the primary resistance mechanisms. Most patients received combination antimicrobial therapy for a median of 17 days. An alarmingly high mortality rate at 34% was found. Conclusions: Our findings highlight that CRE-BSIs pose a significant threat to children with underlying conditions in LAC, leading to substantial morbidity and mortality. Implementing robust antimicrobial stewardship programs and effective infection control measures are crucial to curbing the spread of CRE-BSIs in the region. This review underscores the need for targeted interventions and further research to address this critical public health concern in pediatric populations across LAC.
引用
收藏
页数:12
相关论文
共 49 条
  • [1] Carbapenem-resistant Klebsiella pneumoniae colonization in pediatric and neonatal intensive care units: risk factors for progression to infection
    Akturk, Hacer
    Sutcu, Murat
    Somer, Ayper
    Aydin, Derya
    Cihan, Rukiye
    Ozdemir, Asli
    Coban, Asuman
    Ince, Zeynep
    Citak, Agop
    Salman, Nuran
    [J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2016, 20 (02) : 134 - 140
  • [2] Carbapenem-resistant Gram-negative bloodstream infections in critically ill children: outcome and risk factors in a tertiary teaching hospital in South America
    Alvares, P. A.
    Arnoni, M. V.
    da Silva, C. B.
    Safadi, M. A. P.
    Mimica, M. J.
    [J]. JOURNAL OF HOSPITAL INFECTION, 2019, 101 (02) : 188 - 189
  • [3] [Anonymous], Study Quality Assessment Tools | NHLBI
  • [4] Carbapenemase-producing Enterobacteriaceae in Mexico: report of seven non-clonal cases in a pediatric hospital
    Aquino-Andrade, Alejandra
    Merida-Vieyra, Jocelin
    Arias de la Garza, Eduardo
    Arzate-Barbosa, Patricia
    De Colsa Ranero, Agustin
    [J]. BMC MICROBIOLOGY, 2018, 18
  • [5] Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children
    Ara-Montojo, M. F.
    Escosa-Garcia, L.
    Alguacil-Guillen, M.
    Seara, N.
    Zozaya, C.
    Plaza, D.
    Schuffelmann-Gutierrez, C.
    de la Vega, A.
    Fernandez-Camblor, C.
    Ramos-Boluda, E.
    Romero-Gomez, M. P.
    Ruiz-Carrascoso, G.
    Losantos-Garcia, I
    Mellado-Pena, M. J.
    Gomez-Gil, R.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (01) : 220 - 225
  • [6] How to perform a meta-analysis with R: a practical tutorial
    Balduzzi, Sara
    Ruecker, Gerta
    Schwarzer, Guido
    [J]. EVIDENCE-BASED MENTAL HEALTH, 2019, 22 (04) : 153 - 160
  • [7] Carbapenemase-Producing Organisms: A Global Scourge
    Bonomo, Robert A.
    Burd, Eileen M.
    Conly, John
    Limbago, Brandi M.
    Poirel, Laurent
    Segre, Julie A.
    Westblade, Lars F.
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 66 (08) : 1290 - 1297
  • [8] Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America
    Ciapponi, Agustin
    Bardach, Ariel
    Sandoval, Maria Macarena
    Palermo, Maria Carolina
    Navarro, Emiliano
    Espinal, Carlos
    Quiros, Rodolfo
    [J]. EMERGING INFECTIOUS DISEASES, 2023, 29 (11) : 2335 - 2344
  • [9] Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins
    de Oliveira, M. S.
    de Assis, D. B.
    Freire, M. P.
    Boas do Prado, G. V.
    Machado, A. S.
    Abdala, E.
    Pierrotti, L. C.
    Mangini, C.
    Campos, L.
    Caiaffa Filho, H. H.
    Levin, A. S.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (02) : 179.e1 - 179.e7
  • [10] METAANALYSIS IN CLINICAL-TRIALS
    DERSIMONIAN, R
    LAIRD, N
    [J]. CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 177 - 188